サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1799107

喘息治療薬の世界市場

Asthma Drugs

出版日
ページ情報
英文 177 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=148.56円
喘息治療薬の世界市場
出版日: 2025年08月27日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 177 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

喘息治療薬の世界市場は2030年までに331億米ドルに到達

2024年に251億米ドルと推定される喘息治療薬の世界市場は、2024～2030年の分析期間にCAGR 4.7%で成長し、2030年には331億米ドルに達すると予測されます。本レポートで分析したセグメントの1つである気管支拡張剤は、CAGR 5.6%を記録し、分析期間終了時には210億米ドルに達すると予測されます。抗炎症薬セグメントの成長率は、分析期間中CAGR 3.0%と推定されます。

米国市場は68億米ドル、中国はCAGR 8.7％で成長すると予測

米国の喘息治療薬市場は2024年に68億米ドルと推定されます。世界第2位の経済大国である中国は、2030年までに70億米ドルの市場規模に達すると予測され、分析期間2024-2030年のCAGRは8.7%です。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ1.9%と3.7%と予測されています。欧州では、ドイツがCAGR 2.8%で成長すると予測されています。

世界の喘息治療薬市場- 主要動向と促進要因のまとめ

イノベーションは喘息治療薬開発の近代的展望をどのように形成しているか？

世界で3億人以上が罹患している慢性呼吸器疾患である喘息は、医薬品イノベーションの重要な焦点として進化し続けています。喘息治療薬市場は、製剤や標的治療薬の急速な進歩によって著しい変貌を遂げています。過去10年間で、製薬会社は従来のコルチコステロイドベースの治療薬や気管支拡張剤から、より洗練された生物学的製剤やモノクローナル抗体へと移行してきました。オマリズマブ、メポリズマブ、ベンラリズマブ、デュピルマブなどのこれらの標的治療は、単に症状を緩和するのではなく、喘息の根本的な炎症経路に対処するように設計されています。プレシジョン・メディシンとファーマコゲノミクスの統合は、個々の遺伝子プロファイルに合わせた治療を行うことで、薬剤の有効性をさらに高めています。さらに、吸入技術にも多額の投資が行われ、薬剤をより効果的に送達するだけでなく、デジタル接続を介して患者のアドヒアランスや使用パターンを追跡する次世代スマート吸入器が開発されています。開発パイプラインは、好酸球性喘息と非好酸球性喘息の両表現型を対象とした数多くの臨床試験で強固なものとなっており、これまで標準的な治療に反応しなかった患者に新たな希望をもたらしています。FDAやEMAのような規制機関は、新規生物製剤の承認を迅速に進め、希少疾病用医薬品の指定を与えており、業界は、喘息治療の標準を継続的に再定義する持続的な技術革新の態勢を整えています。

人口動態とライフスタイルの変化が新たな市場機会を生み出しているのはなぜか？

世界人口の人口動態の変化は、都市化や環境の変化とともに、喘息治療薬市場に大きな影響を与えています。特にインド、中国、東南アジアの一部など急速に発展している国々では、都市人口が公害、アレルゲン、職業性刺激物にさらされる機会が増加しており、これらすべてが喘息の有病率を高めています。この動向をさらに悪化させているのは、肥満、座りがちな生活、不健康な食習慣の増加であり、これらはすべて喘息増悪の一因であると認識されています。さらに、欧米諸国では人口の高齢化が進んでおり、高齢の喘息患者には、治療戦略や薬剤の安全性プロファイルを調整する必要がある合併症がしばしば見られるため、独自の課題と機会が生じています。小児喘息も依然として大きな懸念事項であるため、製薬会社は風味のある吸入薬、溶解可能な錠剤、副作用の少ないネブライザーなど、小児にやさしい製剤の開発に取り組んでいます。公衆衛生キャンペーンやオンライン教育によって強化された消費者の意識も、診断率の向上や積極的な疾病管理につながっています。多くの市場では、喘息に対する偏見が薄れつつあり、その結果、早期治療や維持療法を求める人が増えています。これらの要因が相まって、ターゲットとする消費者層が変化し、医薬品開発企業は、さまざまな年齢層、併存疾患プロファイル、地域の健康課題に適した製品を多様化する必要に迫られています。

市場アクセスとヘルスケア・インフラは地域成長の決め手になるか？

アクセスのしやすさ、手ごろな価格、ヘルスケアシステムの堅牢性は、引き続き喘息治療薬市場の地域力学を規定します。北米や欧州のような新興国市場は、高度な医療インフラ、包括的な保険制度、医師の意識の高さを特徴としており、これらすべてが早期診断と持続的な服薬アドヒアランスに寄与しています。これらの地域では、高価な生物製剤や併用療法の価格戦略は、償還の枠組みや公的医療制度によって支えられています。一方、中低所得国では、過小診断、専門医による治療への不十分なアクセス、高額治療の市場浸透を制限する自己負担医療費に悩まされています。しかし、WHOやGINAといった世界の組織が地方政府と連携して、手頃な価格のジェネリック医薬品や標準的な治療プロトコルを推奨することで、必須喘息治療薬へのアクセスを改善しています。遠隔医療やモバイルヘルスプラットフォームは、特に肺専門医が少ない地域で、遠隔診察や投薬モニタリングを可能にし、農村部や十分な医療が行き届いていない地域でますます重要な役割を果たしています。また、多国籍製薬企業は、流通コストを削減し、地域の規制要件を遵守するために、現地のメーカーと戦略的パートナーシップを結んでいます。公衆衛生上の課題として慢性呼吸器疾患を優先する国が増える中、ヘルスケアへのアクセスと患者教育への投資を条件として、新興市場は大きく成長する舞台が整いつつあります。

この決定的瞬間に市場拡大を牽引する基本的な力とは？

喘息治療薬市場の成長は、技術革新、治療需要パターン、消費者行動、ヘルスケアシステムの進化に関連するいくつかの要因によって牽引されています。第一に、生物学的製剤と標的免疫療法の技術進歩により、中等度から重度の喘息まで対応する新しいクラスの非常に効果的な治療法が創出され、より広範な患者にアピールしています。スマート吸入器とデジタル治療薬の普及は、ドラッグデリバリーを再構築し、より正確な投与とリアルタイムのモニタリングを可能にし、コンプライアンスと治療成績を向上させています。第二に、特に都市部や工業化地域における喘息罹患率の上昇により、急性療法と維持療法の両方を必要とする患者数が増加しています。また、消費者の行動も変化しており、患者の健康意識が高まり、デジタル情報を入手するようになり、消極的な治療よりも予防治療に傾倒するようになっています。このため、維持療法薬や個別化された治療レジメンへの需要が高まっています。一方、ヘルスケアプロバイダーは、喘息治療をプライマリーヘルスサービスに統合し、定期的なスクリーニングを増やし、データ分析を活用してハイリスク者を特定することで適応しています。最終的な使用環境としては、病院、専門クリニック、さらには在宅医療の現場でも、携帯型ドラッグデリバリーシステムや遠隔モニタリングソリューションの進歩により、喘息治療薬の使用が拡大しています。最後に、良好な政策支援、大気汚染削減のための世界の取り組み、医薬品へのアクセスと購入しやすさの向上を目指した官民パートナーシップは、先進国、新興国双方の地域において、市場の持続的成長を促す環境を作り出しています。

セグメント

薬剤クラス別（気管支拡張薬、抗炎症薬、モノクローナル抗体配合薬）

調査対象企業の例

  • AbbVie Inc.
  • Amgen Inc.
  • AstraZeneca plc
  • Boehringer Ingelheim
  • Chiesi Farmaceutici S.p.A
  • Cipla Ltd.
  • Covis Pharma
  • Gedeon Richter Plc
  • Glenmark Pharmaceuticals
  • GSK plc（GlaxoSmithKline）
  • Kyorin Pharmaceutical Co.
  • Lupin Limited
  • Merck & Co., Inc.
  • Novartis AG
  • Orion Corporation
  • Sanofi S.A.
  • Sun Pharmaceutical
  • Teva Pharmaceutical
  • Theravance Biopharma
  • Vectura Group

AI統合

当社は、有効な専門家コンテンツとAIツールにより、市場と競合情報を変革しています。

Global Industry Analystsは、LLMや業界固有のSLMを照会する一般的な規範に従う代わりに、ビデオ記録、ブログ、検索エンジン調査、膨大な量の企業、製品/サービス、市場データなど、世界中の専門家から収集したコンテンツのリポジトリを構築しました。

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、売上原価（COGS）の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • スペイン
  • ロシア
  • その他欧州
  • アジア太平洋
  • オーストラリア
  • インド
  • 韓国
  • その他アジア太平洋地域
  • ラテンアメリカ
  • アルゼンチン
  • ブラジル
  • メキシコ
  • その他ラテンアメリカ
  • 中東
  • イラン
  • イスラエル
  • サウジアラビア
  • アラブ首長国連邦
  • その他中東
  • アフリカ

第4章 競合

目次
Product Code: MCP38503

Global Asthma Drugs Market to Reach US$33.1 Billion by 2030

The global market for Asthma Drugs estimated at US$25.1 Billion in the year 2024, is expected to reach US$33.1 Billion by 2030, growing at a CAGR of 4.7% over the analysis period 2024-2030. Bronchodilators, one of the segments analyzed in the report, is expected to record a 5.6% CAGR and reach US$21.0 Billion by the end of the analysis period. Growth in the Anti-inflammatory Drugs segment is estimated at 3.0% CAGR over the analysis period.

The U.S. Market is Estimated at US$6.8 Billion While China is Forecast to Grow at 8.7% CAGR

The Asthma Drugs market in the U.S. is estimated at US$6.8 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$7.0 Billion by the year 2030 trailing a CAGR of 8.7% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.9% and 3.7% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 2.8% CAGR.

Global Asthma Drugs Market - Key Trends & Drivers Summarized

How Is Innovation Shaping the Modern Landscape of Asthma Drug Development?

Asthma, a chronic respiratory condition affecting over 300 million people globally, continues to evolve as a key focal point for pharmaceutical innovation. The asthma drugs market has been undergoing a remarkable transformation driven by rapid advancements in drug formulations and targeted therapies. Over the past decade, pharmaceutical companies have moved away from traditional corticosteroid-based therapies and bronchodilators toward more sophisticated biologics and monoclonal antibodies. These targeted treatments such as omalizumab, mepolizumab, benralizumab, and dupilumab are designed to address the underlying inflammatory pathways of asthma rather than merely alleviating symptoms. The integration of precision medicine and pharmacogenomics has further enhanced drug efficacy by tailoring treatments to individual genetic profiles. Moreover, there has been significant investment in inhalation technology, resulting in next-generation smart inhalers that not only deliver drugs more effectively but also track patient adherence and usage patterns via digital connectivity. The development pipeline remains robust with numerous clinical trials targeting both eosinophilic and non-eosinophilic asthma phenotypes, offering renewed hope for patients previously unresponsive to standard therapies. With regulatory bodies like the FDA and EMA fast-tracking approvals for novel biologics and granting orphan drug designations, the industry is poised for sustained innovation that continually redefines the standard of asthma care.

Why Are Shifting Demographics and Lifestyle Patterns Creating New Market Opportunities?

The changing demographics of the global population, alongside urbanization and environmental shifts, are significantly impacting the asthma drugs market. Urban populations, particularly in rapidly developing nations such as India, China, and parts of Southeast Asia, are experiencing increased exposure to pollution, allergens, and occupational irritants, all of which elevate asthma prevalence rates. Compounding this trend is the rise in obesity, sedentary lifestyles, and unhealthy dietary habits, all of which are recognized contributors to asthma exacerbation. Additionally, aging populations in Western economies are presenting unique challenges and opportunities, as elderly asthma patients often have comorbidities that necessitate tailored therapeutic strategies and drug safety profiles. Pediatric asthma, too, remains a major concern, prompting pharmaceutical firms to develop child-friendly formulations, including flavored inhalers, dissolvable tablets, and nebulized solutions with minimal side effects. Consumer awareness, bolstered by public health campaigns and online education, has also led to increased diagnosis rates and proactive disease management. In many markets, the stigma around asthma is diminishing, resulting in more people seeking early treatment and maintenance therapy, which, in turn, drives demand for preventive medications and long-term care options. Together, these factors are shifting the target consumer base and compelling drug developers to diversify product offerings suited to different age groups, comorbidity profiles, and regional health challenges.

Could Market Access and Healthcare Infrastructure Be the Decisive Factors in Regional Growth?

Accessibility, affordability, and the robustness of healthcare systems continue to define the regional dynamics of the asthma drugs market. Developed markets such as North America and Europe are characterized by advanced healthcare infrastructure, comprehensive insurance coverage, and high levels of physician awareness, all of which contribute to early diagnosis and sustained drug adherence. In these regions, pricing strategies for premium biologics and combination therapies are supported by reimbursement frameworks and public healthcare systems. On the other hand, low- and middle-income countries are grappling with underdiagnosis, inadequate access to specialist care, and out-of-pocket healthcare expenditures that limit market penetration for high-cost treatments. However, initiatives from global organizations such as WHO and GINA, in partnership with local governments, are improving access to essential asthma medications by endorsing affordable generics and standard treatment protocols. Telemedicine and mobile health platforms are playing an increasingly critical role in rural and underserved areas, enabling remote consultations and medication monitoring, especially in geographies where pulmonologists are scarce. Multinational pharma companies are also engaging in strategic partnerships with local manufacturers to reduce distribution costs and comply with regional regulatory requirements. As more countries prioritize chronic respiratory conditions within their public health agendas, the stage is set for significant growth in emerging markets, contingent on investments in healthcare access and patient education.

What Are the Underlying Forces Driving Market Expansion at This Decisive Moment?

The growth in the asthma drugs market is driven by several factors related to technology innovation, therapeutic demand patterns, consumer behavior, and healthcare system evolution. First, the technological progress in biologics and targeted immunotherapies has created a new class of highly effective treatments that address both moderate and severe forms of asthma, appealing to a broader spectrum of patients. The proliferation of smart inhalers and digital therapeutics is reshaping drug delivery, enabling more precise dosing and real-time monitoring, which improves compliance and treatment outcomes. Secondly, the rising incidence of asthma, particularly in urban and industrializing regions, is increasing the patient population requiring both acute and maintenance therapies. Consumer behavior is also shifting, with patients becoming more health-conscious, digitally informed, and inclined toward preventive care rather than reactive treatment. This has elevated demand for maintenance drugs and personalized treatment regimens. Meanwhile, healthcare providers are adapting by integrating asthma care into primary health services, increasing routine screening, and leveraging data analytics to identify high-risk individuals. In terms of end-use environments, hospitals, specialty clinics, and even home care settings are expanding their use of asthma drugs due to advancements in portable drug delivery systems and remote monitoring solutions. Finally, favorable policy support, global initiatives to reduce air pollution, and public-private partnerships aimed at improving drug access and affordability are creating a conducive environment for sustained market growth across both developed and emerging regions.

SCOPE OF STUDY:

The report analyzes the Asthma Drugs market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Drug Class (Bronchodilators, Anti-inflammatory Drugs, Monoclonal Antibodies Combination Drugs)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 36 Featured) -

  • AbbVie Inc.
  • Amgen Inc.
  • AstraZeneca plc
  • Boehringer Ingelheim
  • Chiesi Farmaceutici S.p.A
  • Cipla Ltd.
  • Covis Pharma
  • Gedeon Richter Plc
  • Glenmark Pharmaceuticals
  • GSK plc (GlaxoSmithKline)
  • Kyorin Pharmaceutical Co.
  • Lupin Limited
  • Merck & Co., Inc.
  • Novartis AG
  • Orion Corporation
  • Sanofi S.A.
  • Sun Pharmaceutical
  • Teva Pharmaceutical
  • Theravance Biopharma
  • Vectura Group

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Tariff Impact on Global Supply Chain Patterns
    • Asthma Drugs - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Biologics Boom Throws the Spotlight on Monoclonal Antibodies as the Future of Severe Asthma Treatment
    • Digital Health Integration Spurs Growth in Personalized Asthma Therapy Management
    • Rising Global Pollution Levels Expand the Addressable Market Opportunity for Asthma Medications
    • Inhaler Technology Advancements Strengthen the Business Case for Device-Drug Combinations
    • Aging Population and Comorbidities Generate Sustained Demand for Long-Term Asthma Control Solutions
    • Real-World Evidence (RWE) Strategies Propel Growth in Label Expansion and Reimbursement Approvals
    • Growing Emphasis on Environmental Sustainability Creates Challenges for Propellant-Based Inhalers
    • Telemedicine Penetration Accelerates Demand for Remote Prescription and Symptom Monitoring Solutions
    • Rising Asthma Prevalence in Emerging Economies Expands Market Penetration Opportunities
    • Precision Medicine Approaches Drive Interest in Biomarker-Based Asthma Drug Development
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Asthma Drugs Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Asthma Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Asthma Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 4: World 16-Year Perspective for Asthma Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Bronchodilators by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Bronchodilators by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 7: World 16-Year Perspective for Bronchodilators by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Anti-inflammatory Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Anti-inflammatory Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 10: World 16-Year Perspective for Anti-inflammatory Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Monoclonal Antibodies Combination Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Monoclonal Antibodies Combination Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 13: World 16-Year Perspective for Monoclonal Antibodies Combination Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Asthma Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 14: USA Recent Past, Current & Future Analysis for Asthma Drugs by Drug Class - Bronchodilators, Anti-inflammatory Drugs and Monoclonal Antibodies Combination Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 15: USA Historic Review for Asthma Drugs by Drug Class - Bronchodilators, Anti-inflammatory Drugs and Monoclonal Antibodies Combination Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 16: USA 16-Year Perspective for Asthma Drugs by Drug Class - Percentage Breakdown of Value Sales for Bronchodilators, Anti-inflammatory Drugs and Monoclonal Antibodies Combination Drugs for the Years 2014, 2025 & 2030
  • CANADA
    • TABLE 17: Canada Recent Past, Current & Future Analysis for Asthma Drugs by Drug Class - Bronchodilators, Anti-inflammatory Drugs and Monoclonal Antibodies Combination Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 18: Canada Historic Review for Asthma Drugs by Drug Class - Bronchodilators, Anti-inflammatory Drugs and Monoclonal Antibodies Combination Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 19: Canada 16-Year Perspective for Asthma Drugs by Drug Class - Percentage Breakdown of Value Sales for Bronchodilators, Anti-inflammatory Drugs and Monoclonal Antibodies Combination Drugs for the Years 2014, 2025 & 2030
  • JAPAN
    • Asthma Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 20: Japan Recent Past, Current & Future Analysis for Asthma Drugs by Drug Class - Bronchodilators, Anti-inflammatory Drugs and Monoclonal Antibodies Combination Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 21: Japan Historic Review for Asthma Drugs by Drug Class - Bronchodilators, Anti-inflammatory Drugs and Monoclonal Antibodies Combination Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 22: Japan 16-Year Perspective for Asthma Drugs by Drug Class - Percentage Breakdown of Value Sales for Bronchodilators, Anti-inflammatory Drugs and Monoclonal Antibodies Combination Drugs for the Years 2014, 2025 & 2030
  • CHINA
    • Asthma Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 23: China Recent Past, Current & Future Analysis for Asthma Drugs by Drug Class - Bronchodilators, Anti-inflammatory Drugs and Monoclonal Antibodies Combination Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 24: China Historic Review for Asthma Drugs by Drug Class - Bronchodilators, Anti-inflammatory Drugs and Monoclonal Antibodies Combination Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 25: China 16-Year Perspective for Asthma Drugs by Drug Class - Percentage Breakdown of Value Sales for Bronchodilators, Anti-inflammatory Drugs and Monoclonal Antibodies Combination Drugs for the Years 2014, 2025 & 2030
  • EUROPE
    • Asthma Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 26: Europe Recent Past, Current & Future Analysis for Asthma Drugs by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 27: Europe Historic Review for Asthma Drugs by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 28: Europe 16-Year Perspective for Asthma Drugs by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2025 & 2030
    • TABLE 29: Europe Recent Past, Current & Future Analysis for Asthma Drugs by Drug Class - Bronchodilators, Anti-inflammatory Drugs and Monoclonal Antibodies Combination Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 30: Europe Historic Review for Asthma Drugs by Drug Class - Bronchodilators, Anti-inflammatory Drugs and Monoclonal Antibodies Combination Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 31: Europe 16-Year Perspective for Asthma Drugs by Drug Class - Percentage Breakdown of Value Sales for Bronchodilators, Anti-inflammatory Drugs and Monoclonal Antibodies Combination Drugs for the Years 2014, 2025 & 2030
  • FRANCE
    • Asthma Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 32: France Recent Past, Current & Future Analysis for Asthma Drugs by Drug Class - Bronchodilators, Anti-inflammatory Drugs and Monoclonal Antibodies Combination Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 33: France Historic Review for Asthma Drugs by Drug Class - Bronchodilators, Anti-inflammatory Drugs and Monoclonal Antibodies Combination Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 34: France 16-Year Perspective for Asthma Drugs by Drug Class - Percentage Breakdown of Value Sales for Bronchodilators, Anti-inflammatory Drugs and Monoclonal Antibodies Combination Drugs for the Years 2014, 2025 & 2030
  • GERMANY
    • Asthma Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 35: Germany Recent Past, Current & Future Analysis for Asthma Drugs by Drug Class - Bronchodilators, Anti-inflammatory Drugs and Monoclonal Antibodies Combination Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 36: Germany Historic Review for Asthma Drugs by Drug Class - Bronchodilators, Anti-inflammatory Drugs and Monoclonal Antibodies Combination Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 37: Germany 16-Year Perspective for Asthma Drugs by Drug Class - Percentage Breakdown of Value Sales for Bronchodilators, Anti-inflammatory Drugs and Monoclonal Antibodies Combination Drugs for the Years 2014, 2025 & 2030
  • ITALY
    • TABLE 38: Italy Recent Past, Current & Future Analysis for Asthma Drugs by Drug Class - Bronchodilators, Anti-inflammatory Drugs and Monoclonal Antibodies Combination Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 39: Italy Historic Review for Asthma Drugs by Drug Class - Bronchodilators, Anti-inflammatory Drugs and Monoclonal Antibodies Combination Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 40: Italy 16-Year Perspective for Asthma Drugs by Drug Class - Percentage Breakdown of Value Sales for Bronchodilators, Anti-inflammatory Drugs and Monoclonal Antibodies Combination Drugs for the Years 2014, 2025 & 2030
  • UNITED KINGDOM
    • Asthma Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 41: UK Recent Past, Current & Future Analysis for Asthma Drugs by Drug Class - Bronchodilators, Anti-inflammatory Drugs and Monoclonal Antibodies Combination Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 42: UK Historic Review for Asthma Drugs by Drug Class - Bronchodilators, Anti-inflammatory Drugs and Monoclonal Antibodies Combination Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 43: UK 16-Year Perspective for Asthma Drugs by Drug Class - Percentage Breakdown of Value Sales for Bronchodilators, Anti-inflammatory Drugs and Monoclonal Antibodies Combination Drugs for the Years 2014, 2025 & 2030
  • SPAIN
    • TABLE 44: Spain Recent Past, Current & Future Analysis for Asthma Drugs by Drug Class - Bronchodilators, Anti-inflammatory Drugs and Monoclonal Antibodies Combination Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 45: Spain Historic Review for Asthma Drugs by Drug Class - Bronchodilators, Anti-inflammatory Drugs and Monoclonal Antibodies Combination Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 46: Spain 16-Year Perspective for Asthma Drugs by Drug Class - Percentage Breakdown of Value Sales for Bronchodilators, Anti-inflammatory Drugs and Monoclonal Antibodies Combination Drugs for the Years 2014, 2025 & 2030
  • RUSSIA
    • TABLE 47: Russia Recent Past, Current & Future Analysis for Asthma Drugs by Drug Class - Bronchodilators, Anti-inflammatory Drugs and Monoclonal Antibodies Combination Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 48: Russia Historic Review for Asthma Drugs by Drug Class - Bronchodilators, Anti-inflammatory Drugs and Monoclonal Antibodies Combination Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 49: Russia 16-Year Perspective for Asthma Drugs by Drug Class - Percentage Breakdown of Value Sales for Bronchodilators, Anti-inflammatory Drugs and Monoclonal Antibodies Combination Drugs for the Years 2014, 2025 & 2030
  • REST OF EUROPE
    • TABLE 50: Rest of Europe Recent Past, Current & Future Analysis for Asthma Drugs by Drug Class - Bronchodilators, Anti-inflammatory Drugs and Monoclonal Antibodies Combination Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 51: Rest of Europe Historic Review for Asthma Drugs by Drug Class - Bronchodilators, Anti-inflammatory Drugs and Monoclonal Antibodies Combination Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 52: Rest of Europe 16-Year Perspective for Asthma Drugs by Drug Class - Percentage Breakdown of Value Sales for Bronchodilators, Anti-inflammatory Drugs and Monoclonal Antibodies Combination Drugs for the Years 2014, 2025 & 2030
  • ASIA-PACIFIC
    • Asthma Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 53: Asia-Pacific Recent Past, Current & Future Analysis for Asthma Drugs by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 54: Asia-Pacific Historic Review for Asthma Drugs by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 55: Asia-Pacific 16-Year Perspective for Asthma Drugs by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2025 & 2030
    • TABLE 56: Asia-Pacific Recent Past, Current & Future Analysis for Asthma Drugs by Drug Class - Bronchodilators, Anti-inflammatory Drugs and Monoclonal Antibodies Combination Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Asia-Pacific Historic Review for Asthma Drugs by Drug Class - Bronchodilators, Anti-inflammatory Drugs and Monoclonal Antibodies Combination Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 58: Asia-Pacific 16-Year Perspective for Asthma Drugs by Drug Class - Percentage Breakdown of Value Sales for Bronchodilators, Anti-inflammatory Drugs and Monoclonal Antibodies Combination Drugs for the Years 2014, 2025 & 2030
  • AUSTRALIA
    • Asthma Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 59: Australia Recent Past, Current & Future Analysis for Asthma Drugs by Drug Class - Bronchodilators, Anti-inflammatory Drugs and Monoclonal Antibodies Combination Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 60: Australia Historic Review for Asthma Drugs by Drug Class - Bronchodilators, Anti-inflammatory Drugs and Monoclonal Antibodies Combination Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 61: Australia 16-Year Perspective for Asthma Drugs by Drug Class - Percentage Breakdown of Value Sales for Bronchodilators, Anti-inflammatory Drugs and Monoclonal Antibodies Combination Drugs for the Years 2014, 2025 & 2030
  • INDIA
    • Asthma Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 62: India Recent Past, Current & Future Analysis for Asthma Drugs by Drug Class - Bronchodilators, Anti-inflammatory Drugs and Monoclonal Antibodies Combination Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 63: India Historic Review for Asthma Drugs by Drug Class - Bronchodilators, Anti-inflammatory Drugs and Monoclonal Antibodies Combination Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 64: India 16-Year Perspective for Asthma Drugs by Drug Class - Percentage Breakdown of Value Sales for Bronchodilators, Anti-inflammatory Drugs and Monoclonal Antibodies Combination Drugs for the Years 2014, 2025 & 2030
  • SOUTH KOREA
    • TABLE 65: South Korea Recent Past, Current & Future Analysis for Asthma Drugs by Drug Class - Bronchodilators, Anti-inflammatory Drugs and Monoclonal Antibodies Combination Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 66: South Korea Historic Review for Asthma Drugs by Drug Class - Bronchodilators, Anti-inflammatory Drugs and Monoclonal Antibodies Combination Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 67: South Korea 16-Year Perspective for Asthma Drugs by Drug Class - Percentage Breakdown of Value Sales for Bronchodilators, Anti-inflammatory Drugs and Monoclonal Antibodies Combination Drugs for the Years 2014, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 68: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Asthma Drugs by Drug Class - Bronchodilators, Anti-inflammatory Drugs and Monoclonal Antibodies Combination Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Rest of Asia-Pacific Historic Review for Asthma Drugs by Drug Class - Bronchodilators, Anti-inflammatory Drugs and Monoclonal Antibodies Combination Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 70: Rest of Asia-Pacific 16-Year Perspective for Asthma Drugs by Drug Class - Percentage Breakdown of Value Sales for Bronchodilators, Anti-inflammatory Drugs and Monoclonal Antibodies Combination Drugs for the Years 2014, 2025 & 2030
  • LATIN AMERICA
    • Asthma Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 71: Latin America Recent Past, Current & Future Analysis for Asthma Drugs by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 72: Latin America Historic Review for Asthma Drugs by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 73: Latin America 16-Year Perspective for Asthma Drugs by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2025 & 2030
    • TABLE 74: Latin America Recent Past, Current & Future Analysis for Asthma Drugs by Drug Class - Bronchodilators, Anti-inflammatory Drugs and Monoclonal Antibodies Combination Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Latin America Historic Review for Asthma Drugs by Drug Class - Bronchodilators, Anti-inflammatory Drugs and Monoclonal Antibodies Combination Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 76: Latin America 16-Year Perspective for Asthma Drugs by Drug Class - Percentage Breakdown of Value Sales for Bronchodilators, Anti-inflammatory Drugs and Monoclonal Antibodies Combination Drugs for the Years 2014, 2025 & 2030
  • ARGENTINA
    • TABLE 77: Argentina Recent Past, Current & Future Analysis for Asthma Drugs by Drug Class - Bronchodilators, Anti-inflammatory Drugs and Monoclonal Antibodies Combination Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 78: Argentina Historic Review for Asthma Drugs by Drug Class - Bronchodilators, Anti-inflammatory Drugs and Monoclonal Antibodies Combination Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 79: Argentina 16-Year Perspective for Asthma Drugs by Drug Class - Percentage Breakdown of Value Sales for Bronchodilators, Anti-inflammatory Drugs and Monoclonal Antibodies Combination Drugs for the Years 2014, 2025 & 2030
  • BRAZIL
    • TABLE 80: Brazil Recent Past, Current & Future Analysis for Asthma Drugs by Drug Class - Bronchodilators, Anti-inflammatory Drugs and Monoclonal Antibodies Combination Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: Brazil Historic Review for Asthma Drugs by Drug Class - Bronchodilators, Anti-inflammatory Drugs and Monoclonal Antibodies Combination Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 82: Brazil 16-Year Perspective for Asthma Drugs by Drug Class - Percentage Breakdown of Value Sales for Bronchodilators, Anti-inflammatory Drugs and Monoclonal Antibodies Combination Drugs for the Years 2014, 2025 & 2030
  • MEXICO
    • TABLE 83: Mexico Recent Past, Current & Future Analysis for Asthma Drugs by Drug Class - Bronchodilators, Anti-inflammatory Drugs and Monoclonal Antibodies Combination Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 84: Mexico Historic Review for Asthma Drugs by Drug Class - Bronchodilators, Anti-inflammatory Drugs and Monoclonal Antibodies Combination Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 85: Mexico 16-Year Perspective for Asthma Drugs by Drug Class - Percentage Breakdown of Value Sales for Bronchodilators, Anti-inflammatory Drugs and Monoclonal Antibodies Combination Drugs for the Years 2014, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 86: Rest of Latin America Recent Past, Current & Future Analysis for Asthma Drugs by Drug Class - Bronchodilators, Anti-inflammatory Drugs and Monoclonal Antibodies Combination Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Rest of Latin America Historic Review for Asthma Drugs by Drug Class - Bronchodilators, Anti-inflammatory Drugs and Monoclonal Antibodies Combination Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 88: Rest of Latin America 16-Year Perspective for Asthma Drugs by Drug Class - Percentage Breakdown of Value Sales for Bronchodilators, Anti-inflammatory Drugs and Monoclonal Antibodies Combination Drugs for the Years 2014, 2025 & 2030
  • MIDDLE EAST
    • Asthma Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 89: Middle East Recent Past, Current & Future Analysis for Asthma Drugs by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 90: Middle East Historic Review for Asthma Drugs by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 91: Middle East 16-Year Perspective for Asthma Drugs by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2025 & 2030
    • TABLE 92: Middle East Recent Past, Current & Future Analysis for Asthma Drugs by Drug Class - Bronchodilators, Anti-inflammatory Drugs and Monoclonal Antibodies Combination Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Middle East Historic Review for Asthma Drugs by Drug Class - Bronchodilators, Anti-inflammatory Drugs and Monoclonal Antibodies Combination Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 94: Middle East 16-Year Perspective for Asthma Drugs by Drug Class - Percentage Breakdown of Value Sales for Bronchodilators, Anti-inflammatory Drugs and Monoclonal Antibodies Combination Drugs for the Years 2014, 2025 & 2030
  • IRAN
    • TABLE 95: Iran Recent Past, Current & Future Analysis for Asthma Drugs by Drug Class - Bronchodilators, Anti-inflammatory Drugs and Monoclonal Antibodies Combination Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Iran Historic Review for Asthma Drugs by Drug Class - Bronchodilators, Anti-inflammatory Drugs and Monoclonal Antibodies Combination Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 97: Iran 16-Year Perspective for Asthma Drugs by Drug Class - Percentage Breakdown of Value Sales for Bronchodilators, Anti-inflammatory Drugs and Monoclonal Antibodies Combination Drugs for the Years 2014, 2025 & 2030
  • ISRAEL
    • TABLE 98: Israel Recent Past, Current & Future Analysis for Asthma Drugs by Drug Class - Bronchodilators, Anti-inflammatory Drugs and Monoclonal Antibodies Combination Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Israel Historic Review for Asthma Drugs by Drug Class - Bronchodilators, Anti-inflammatory Drugs and Monoclonal Antibodies Combination Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 100: Israel 16-Year Perspective for Asthma Drugs by Drug Class - Percentage Breakdown of Value Sales for Bronchodilators, Anti-inflammatory Drugs and Monoclonal Antibodies Combination Drugs for the Years 2014, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 101: Saudi Arabia Recent Past, Current & Future Analysis for Asthma Drugs by Drug Class - Bronchodilators, Anti-inflammatory Drugs and Monoclonal Antibodies Combination Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Saudi Arabia Historic Review for Asthma Drugs by Drug Class - Bronchodilators, Anti-inflammatory Drugs and Monoclonal Antibodies Combination Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 103: Saudi Arabia 16-Year Perspective for Asthma Drugs by Drug Class - Percentage Breakdown of Value Sales for Bronchodilators, Anti-inflammatory Drugs and Monoclonal Antibodies Combination Drugs for the Years 2014, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 104: UAE Recent Past, Current & Future Analysis for Asthma Drugs by Drug Class - Bronchodilators, Anti-inflammatory Drugs and Monoclonal Antibodies Combination Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 105: UAE Historic Review for Asthma Drugs by Drug Class - Bronchodilators, Anti-inflammatory Drugs and Monoclonal Antibodies Combination Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 106: UAE 16-Year Perspective for Asthma Drugs by Drug Class - Percentage Breakdown of Value Sales for Bronchodilators, Anti-inflammatory Drugs and Monoclonal Antibodies Combination Drugs for the Years 2014, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 107: Rest of Middle East Recent Past, Current & Future Analysis for Asthma Drugs by Drug Class - Bronchodilators, Anti-inflammatory Drugs and Monoclonal Antibodies Combination Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 108: Rest of Middle East Historic Review for Asthma Drugs by Drug Class - Bronchodilators, Anti-inflammatory Drugs and Monoclonal Antibodies Combination Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 109: Rest of Middle East 16-Year Perspective for Asthma Drugs by Drug Class - Percentage Breakdown of Value Sales for Bronchodilators, Anti-inflammatory Drugs and Monoclonal Antibodies Combination Drugs for the Years 2014, 2025 & 2030
  • AFRICA
    • Asthma Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 110: Africa Recent Past, Current & Future Analysis for Asthma Drugs by Drug Class - Bronchodilators, Anti-inflammatory Drugs and Monoclonal Antibodies Combination Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 111: Africa Historic Review for Asthma Drugs by Drug Class - Bronchodilators, Anti-inflammatory Drugs and Monoclonal Antibodies Combination Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 112: Africa 16-Year Perspective for Asthma Drugs by Drug Class - Percentage Breakdown of Value Sales for Bronchodilators, Anti-inflammatory Drugs and Monoclonal Antibodies Combination Drugs for the Years 2014, 2025 & 2030

IV. COMPETITION